Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Core Viewpoint - Atossa Therapeutics expresses disappointment over the Patent Trial and Appeal Board's decision to invalidate claims in U.S. Patent No. 11,572,334, but this decision does not affect its current clinical formulations [2][5] Patent Developments - The company is evaluating options following the PTAB's ruling but will not appeal due to cost and time considerations, opting instead to pursue additional patent protection through a new Continuation Patent Application [2] - A new patent, U.S. Patent No. 12,201,591, was issued on January 21, 2025, focusing on sustained release compositions of endoxifen, adding to Atossa's patent estate [3][4] Clinical Development - Atossa is developing a proprietary oral formulation of (Z)-endoxifen, which is designed to bypass stomach acidity that deactivates the drug [6] - (Z)-endoxifen is currently undergoing five Phase 2 clinical trials targeting various breast cancer conditions, demonstrating well-tolerated results in earlier studies [6] Company Mission - Atossa Therapeutics is committed to providing innovative treatment options for breast cancer, focusing on (Z)-endoxifen as a potential preventive and therapeutic agent [7]